PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2023-04-04 (2)

Date Title Company
04-Apr-2023 FDA Approves Merck‚Äôs KEYTRUDA® (pembrolizumab) in Combination With Padcev® (enfortumab vedotin-ejfv) for First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer Businesswire